News

Foralumab, a nasal spray therapy that Tiziana Life Sciences is developing for multiple sclerosis (MS) and other disorders, was well-tolerated in mice for more than three months, according to data from a preclinical study. Tiziana is planning to share that data in a meeting with the U.S. Food…

Researchers have created a computer program that can simulate clinical trial responses for relapsing-remitting multiple sclerosis (RRMS), which may improve clinical trial design for novel disease-modifying therapies. The tool, called MS TreatSim, was described in the study, “In silico clinical trials for relapsing-remitting multiple sclerosis…

Genetic variations in certain genes may increase the risk of developing progressive multifocal leukoencephalopathy (PML), a serious brain infection associated with certain treatments for multiple sclerosis (MS) and other conditions, a new study shows. The findings suggest that testing for four specific genetic variant could help to predict…

Abata Therapeutics has chosen its first treatment candidate for development: the T-cell therapy ABA-101 for certain forms of progressive multiple sclerosis (MS). The therapy is now in early studies that aim to support an investigational new drug application or IND — a formal request to U.S. regulatory authorities…

Continuous treatment with Tecfidera (dimethyl fumarate) for more than two years did not slow clinical and radiological measures of disease progression in people with primary progressive multiple sclerosis (PPMS) compared with patients who started treatment after one year. In fact, most PPMS patients remained stable with or without…

Daily exposure to 30 minutes of bright light for two weeks led to clinically significant reductions in fatigue scores among people with multiple sclerosis (MS) in a small clinical trial. “The findings from our study represent a promising non-drug therapeutic approach,” Stefan Seidel, PhD, co-author of the study…

A machine learning algorithm that incorporates genetic data alongside clinical and demographic information may be able to more accurately predict the severity of multiple sclerosis (MS), according to a new study. “Once independently validated, the machine learning algorithm could enable clinicians to provide patients with more accurate prognostic information,…

More than four years of treatment with Gilenya (fingolimod) did not cause significant swelling of the macula — a part of the retina, found in the back of the eye, and important for visual clarity — in people with relapsing-remitting multiple sclerosis (RRMS), a small study showed. While…

Noninvasive brain stimulation (NIBS) may be able to reduce fatigue, spasticity, and pain, and improve quality of life in patients with multiple sclerosis (MS), a new meta-analysis reports. The review assessed several NIBS interventions targeting different brain regions. The results suggest that these techniques can have immediate effects…

The University of British Columbia (UBC) and the VGH & UBC Hospital Foundation have received a CA$33.8 million ($25.24 million) donation to establish a multiple sclerosis (MS) research network focused on developing next-generation cell-based treatments. This private donation, by an unnamed British Columbia-based philanthropist, is thought to be the…

Patient-reported cognition difficulties — called subjective cognitive impairment (SCI) — are associated with current work status and with employment deterioration after two years in people with multiple sclerosis (MS), a new study reports. Depression and anxiety also were linked with work status among these MS patients, but such…

People with relapsing-remitting multiple sclerosis (RRMS) who are stable on rituximab treatment may receive the therapy at extended intervals without risking increased MS disease activity, according to a new study. In fact, a longer lag between infusions could potentially reduce the medication’s side effects, researchers say — noting,…

NeuroScientific Biopharmaceuticals has filed a patent in Australia to protect the use of its lead candidate EmtinB in combination with Teva’s Copaxone (glatiramer acetate injection) as a potential treatment for multiple sclerosis (MS). The patent application (provisional number 2022903564) is based on data from a lab…

Researchers have developed a technique that uses CAR T-cells, a form of cell therapy, to specifically eliminate the self-reactive immune cells that drive multiple sclerosis (MS), without destroying healthy immune cells needed to protect against infection. “Our CAR-T cells were very effective at treating mice that have an MS-like…

Tevogen Bio has announced plans to develop T-cell therapies targeting the Epstein-Barr virus (EBV), a herpes virus known to be a major environmental risk factor for multiple sclerosis (MS). The decision comes on the heels of positive safety data from a proof-of-concept Phase 1 Tevogen trial that…

A reduction in the levels of an inflammatory molecule called chemokine ligand 13 (CXCL13) may serve as a biomarker of treatment response to Aubagio (teriflunomide) among people with relapsing-remitting multiple sclerosis (RRMS), a study suggests. After one year of treatment, patients with no evidence of disease activity…

Two years of treatment with the approved therapy >Copaxone (glatiramer acetate) was found to slow the loss of cerebral gray matter and whole brain volume — two markers of neurodegeneration — in people with relapsing-remitting multiple sclerosis (RRMS). Notably, individuals on Copaxone…

Differences in the composition of the gut microbiome are associated with an altered risk of low immune cell counts as a side effect of treatment with the multiple sclerosis (MS) therapy Tecfidera (dimethyl fumarate). The findings provide further insights on how the gut microbiome — the billions of…

Fewer than 1 in 5 people living with multiple sclerosis (MS) or 10 other neurological conditions in the U.S. are on new-to-market medications. That’s according to a large data study funded by the American Academy of Neurology, which also linked more recently available treatments — those approved in the…

Assessing disease activity from the first to second year after a diagnosis of multiple sclerosis (MS), once treatment has been initiated and stabilized, can help predict long-term disability outcomes. That’s according to the study, “Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term…

Eating a lot of acidic foods like meat, eggs, cheese, and grains — and fewer alkaline ones, such as fruits, vegetables, and milk — is significantly associated with worse depression scores over five years among people with multiple sclerosis (MS), a study found. “The level of depression at the…

Consuming alcohol around dosing time could limit the effectiveness of Tecfidera (dimethyl fumarate) for multiple sclerosis patients, a recent study suggests. Results from the study, which involved lab and mouse experiments, showed alcohol inhibits an enzyme in the liver that’s necessary to break down Tecfidera’s main ingredient, dimethyl…

Daily treatment with an oral antidepressant called bupropion — marketed as Wellbutrin and Zyban, among others — significantly improved some aspects of sexual function in women with multiple sclerosis (MS), according to the results of a randomized trial in Iran. “The results of our study showed bupropion can…

People with good immune responses against the human cytomegalovirus (CMV), a common herpes virus, around the time of their first symptoms of multiple sclerosis (MS) may go on to have a slower disease course, a study has found. Compared with people showing weaker immune responses to CMV, these patients…

Almost two-thirds of a group of 108 secondary progressive multiple sclerosis (SPMS) patients being treated with Mayzent (siponimod) remained stable for at least one year, and about 1 in 5 of them showed improvements, a real-world study from Germany found. Nearly one-third of the total 227 SPMS patients evaluated…

Posterior tibial nerve stimulation (PTNS) — a procedure that delivers electrical stimulation to the bladder through nerves in the leg — can reduce symptoms of an overactive bladder in people with multiple sclerosis (MS), according to results from a small trial. The findings indicate that adding PTNS to pelvic…

In a new collaboration, Brainomix will distribute in Europe a software solution developed by Pixyl that uses deep learning to improve the diagnosis and monitoring of multiple sclerosis (MS) via MRI scans. According to the partners, Pixyl‘s technology can detect abnormalities on magnetic resonance imaging or MRI…

Blocking the activity of Spns2, a transporter of the sphingosine 1-phosphate (S1P) protein, reduced the severity of multiple sclerosis (MS) in a mouse model, a new study shows. The findings point to Spns2 as a new molecular target for MS treatments that could reduce the side effects associated…

People with relapsing-remitting multiple sclerosis (RRMS) who switch to Ocrevus (ocrelizumab) after discontinuing Gilenya (fingolimod) have fewer relapses than those who switch to Mavenclad (cladribine) or Tysabri (natalizumab), according to a new study. Rates of disability worsening were similar for Ocrevus and Tysabri, but patients who switched…

Foralumab nasal spray, an experimental therapy by Tiziana Life Sciences that’s being tested for multiple sclerosis and other autoimmune and nervous system diseases, was found to be safe and able to modulate the immune system in healthy volunteers, a study has found. Researchers failed to detect antibodies…